Linkage from HIV testing to care: A positive test often leads nowhere

Sexually Transmitted Diseases

Volumn 40, Issue 1, 2013, Pages 26-27

  El Sadr, Wafaa M ^a   Gamble, Theresa R ^b   Cohen, Myron S ^c  

^a Department of Medicine   (United States)

^b FAMILY HEALTH INTERNATIONAL   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ANTIVIRAL THERAPY; CD4 LYMPHOCYTE COUNT; EDITORIAL; HEALTH INSURANCE; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAID; MEDICAL FEE; MEDICAL RECORD; PATIENT CARE; VIRUS LOAD;

FEMALE; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMANS; MALE; MEDICAID;

EID: 84871586609     PISSN: 01485717     EISSN: 15374521     Source Type: Journal    
DOI: 10.1097/OLQ.0b013e31827e612b     Document Type: Editorial

References (25)

1. Prejean J, Song R, Hernandez A, et al. Estimated HIV incidence in the United States, 2006-2009. PloS One 2011; 6: e17502.
2. Gardner EM, McLees MP, Steiner JF, et al. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis 2011; 52: 793-800.
3. Centers for Disease Control and Prevention. Challenges in HIV Prevention. 2012. Available at: http://www.cdc.gov/nchhstp/newsroom/docs/HIVFactSheets/ Challenges-508.pdf. Accessed October 8, 2012.
4. Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: A prospective cohort analysis. Lancet 2010; 375: 2092-2098.
5. Anglemyer A, Rutherford GW, Baggaley RC, et al. Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. Cochrane Database Syst Rev 2011: CD009153.
6. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365: 493-505.
7. Writing Committee for the CASCADE Collaboration. Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters. Arch Intern Med 2011; 171: 1560-1569.
8. Sterne JA, May M, Costagliola D, et al. Timing of initiation of anti-retroviral therapy in AIDS-free HIV-1Yinfected patients: A collaborative analysis of 18 HIV cohort studies. Lancet 2009; 373: 1352-1363.
9. Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360: 1815-1826.
10. Cain LE, Logan R, Robins JM, et al. When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: An observational study. Ann Int Med 2011; 154: 509-515.
11. Babiker AG, Emery S, Fatkenheuer G, et al. Considerations in the rationale, design and methods of the Strategic Timing of AntiRetro-viral Treatment (START) study. Clin Trials 2012. [Epub ahead of print].
12. HHS Panel on Antiretroviral Guidelines for Adults and Adolescents: A Working Group of the Office of AIDS Research Advisory Council (OARAC). Guidelines for the use of antiretroviral agents in HIV-1Yinfected adults and adolescents. 2012. Available at: http://aidsinfo.nih.gov/contentfiles/ lvguidelines/adultandadolescentgl.pdf. Accessed October 7, 2012.
13. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral SocietyVUSA panel. JAMA 2012; 308: 387-402.
14. Jenness SM, Myers JE, Neaigus A, et al. Delayed entry into HIV medical care after HIV diagnosis: Risk factors and research methods. AIDS care 2012; 24: 1240-1248.
15. Buchacz K, Armon C, Palella FJ, et al. CD4 cell counts at HIV diagnosis among HIVoutpatient study participants, 2000-2009. AIDS Res Treat 2012; 2012: 869841.
16. Torian LV, Wiewel EW, Liu KL, et al. Risk factors for delayed initiation of medical care after diagnosis of human immunodeficiency virus. Arch Intern Med 2008; 168: 1181-1187.
17. Lessells RJ, Mutevedzi PC, Cooke GS, et al. Retention in HIV care for individuals not yet eligible for antiretroviral therapy: Rural KwaZulu-Natal, South Africa. J Acquir Immune Defic Syndr 2011; 56: e79-e86.
18. Goldman DP, Leibowitz AA, Joyce GF, et al. Insurance status of HIV-infected adults in the post-HAART era: Evidence from the United States. Appl Health Econ Health Policy 2003; 2: 85-90.
19. Bozzette SA, Berry SH, Duan N, et al. The care of HIV-infected adults in the United States. HIV Cost and Services Utilization Study Consortium. N Engl J Med 1998; 339: 1897-1904.
20. Grisso JA, Carson JL, Feldman HI, et al. Epidemiological pitfalls using Medicaid data in reproductive health research. J Matern Fetal Med 1997; 6: 230-236.
21. Levinson DR. Medicaid managed care encounter data: collection and use. 2009. Available at: https://oig.hhs.gov/oei/reports/oei-07-06-00540.pdf. Accessed October 8, 2012.
22. AIDS ACTION. Medicaid Managed Care & HIV/AIDS: A Guide for Community-Based Organizations. Available at: http://www. aidsaction.org/ communications/publications/finalMMCbk1.pdf. Accessed December 10, 2012.
23. El-Sadr WM, Affrunti M, Gamble T, et al. Antiretroviral therapy: A promising HIV prevention strategy? J Acquir Immune Defic Syndr 2010;55(suppl 2): S116-S121.
24. Clinton H. Ending the epidemic: turning the tide together. Paper presented at: XIX International AIDS Conference; July 23, 2012; Washington, DC.
25. McNairy ML, El-Sadr WM. The HIV care continuum: No partial credit given. AIDS 2012; 26: 1735-1738.